Vericel Co. Expected to Earn Q2 2024 Earnings of ($0.08) Per Share (NASDAQ:VCEL)

Vericel Co. (NASDAQ:VCELFree Report) – Research analysts at Leerink Partnrs increased their Q2 2024 EPS estimates for shares of Vericel in a research note issued on Wednesday, May 8th. Leerink Partnrs analyst M. Kratky now anticipates that the biotechnology company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.09). The consensus estimate for Vericel’s current full-year earnings is $0.10 per share. Leerink Partnrs also issued estimates for Vericel’s Q4 2024 earnings at $0.31 EPS, FY2024 earnings at $0.14 EPS, FY2026 earnings at $1.04 EPS, FY2027 earnings at $1.43 EPS and FY2028 earnings at $1.92 EPS.

A number of other research analysts have also recently weighed in on VCEL. StockNews.com cut shares of Vericel from a “hold” rating to a “sell” rating in a report on Friday. HC Wainwright lifted their target price on Vericel from $53.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, May 9th. TheStreet upgraded Vericel from a “d+” rating to a “c-” rating in a report on Monday, January 29th. Finally, Truist Financial reiterated a “buy” rating and issued a $54.00 price objective on shares of Vericel in a research note on Tuesday, March 26th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $46.80.

Get Our Latest Stock Report on VCEL

Vericel Price Performance

NASDAQ VCEL opened at $48.52 on Monday. The company has a market cap of $2.36 billion, a P/E ratio of -4,849.15 and a beta of 1.74. Vericel has a 1-year low of $30.18 and a 1-year high of $53.05. The stock has a 50-day moving average of $47.37 and a two-hundred day moving average of $41.86.

Vericel (NASDAQ:VCELGet Free Report) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Vericel had a return on equity of 0.21% and a net margin of 0.22%. The company had revenue of $51.28 million for the quarter, compared to analyst estimates of $49.07 million. During the same quarter in the previous year, the company earned ($0.16) earnings per share. The firm’s quarterly revenue was up 25.0% compared to the same quarter last year.

Insiders Place Their Bets

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $44.67, for a total transaction of $781,725.00. Following the transaction, the chief executive officer now owns 194,870 shares in the company, valued at approximately $8,704,842.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $44.67, for a total transaction of $781,725.00. Following the sale, the chief executive officer now owns 194,870 shares of the company’s stock, valued at $8,704,842.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert L. Md Zerbe sold 3,278 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total value of $169,046.46. Following the sale, the director now directly owns 23,395 shares in the company, valued at approximately $1,206,480.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,267 shares of company stock worth $2,450,996. 7.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Vericel

Hedge funds have recently added to or reduced their stakes in the business. UniSuper Management Pty Ltd acquired a new position in Vericel in the 1st quarter valued at about $595,000. Hillsdale Investment Management Inc. lifted its stake in shares of Vericel by 8.4% during the first quarter. Hillsdale Investment Management Inc. now owns 119,689 shares of the biotechnology company’s stock valued at $6,226,000 after buying an additional 9,300 shares during the period. Vanguard Group Inc. boosted its position in Vericel by 1.2% during the first quarter. Vanguard Group Inc. now owns 3,413,442 shares of the biotechnology company’s stock worth $177,567,000 after acquiring an additional 39,349 shares during the last quarter. Lindenwold Advisors INC acquired a new position in Vericel in the 1st quarter valued at $215,000. Finally, State Board of Administration of Florida Retirement System lifted its stake in shares of Vericel by 19.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 16,199 shares of the biotechnology company’s stock worth $843,000 after purchasing an additional 2,600 shares during the period.

Vericel Company Profile

(Get Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

See Also

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.